Immune System & Allergies terms

A type of cancer that arises in cells in mucosal tissue that are involved in antibody production.

A type of monoclonal antibody used in cancer detection or therapy.

A drug that is used in a cream to treat certain skin conditions and in a nasal spray to treat sinus problems caused by allergies.

A type of immune cell that has granules (small particles) with enzymes that can kill tumor cells or cells infected with a virus.

A type of leukemia in which large natural killer (NK) cells (a type of white blood cell) that contain granules (small particles) are found in the blood.

A type of immune cell that is one of the first cell types to travel to the site of an infection.

Any of a large group of cancers of lymphocytes (white blood cells).

A type of immune cell that has granules (small particles) with enzymes that can kill tumor cells or cells infected with a virus.

A type of immune cell that has granules (small particles) with enzymes that can kill tumor cells or cells infected with a virus.

A rare type of Hodgkin lymphoma, which is a cancer of the immune system.

A rare type of Hodgkin lymphoma, which is a cancer of the immune system.

Any of a large group of cancers of lymphocytes (white blood cells).

A cell (such as a phagocyte or a macrophage) that responds to many antigens, not just one antigen.

A protein found on the surface of some cancers.

A type of fat obtained in the diet and involved in immunity.

A cancer vaccine comprised of synthetic peptides corresponding to naturally-occurring peptides derived from ovarian cancer cell antigens.

(Other name for: autologous dinitrophenyl-modified ovarian cancer vaccine)

A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene.

A peptide vaccine consisting of 10 synthetic long peptides (SLPs), 25-30 amino acids in size and derived from the middle portion of p53 (amino acids 70-251), mixed with the adjuvant Montanide ISA-51…

A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities.